Type of proton-pump inhibitor and risk of iron deficiency in kidney transplant recipients - results from the TransplantLines Biobank and Cohort Study
| Autor: | Gaston van Hassel, Stefan P Berger, Martin H. de Borst, Rianne M Douwes, Joanna Sophia J Vinke, Daan J Touw, Michele F Eisenga, Stephan J. L. Bakker, Hans Blokzijl, António W Gomes-Neto, Gizem Ayerdem |
|---|---|
| Přispěvatelé: | Groningen Kidney Center (GKC), Groningen Institute for Organ Transplantation (GIOT), Pharmaceutical Analysis, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Medicinal Chemistry and Bioanalysis (MCB), Groningen Research Institute for Asthma and COPD (GRIAC), Biopharmaceuticals, Discovery, Design and Delivery (BDDD) |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
potency medicine.drug_class Proton-pump inhibitor Gastroenterology Intestinal absorption Esomeprazole Cohort Studies iron iron deficiency Internal medicine FERRIC CARBOXYMALTOSE MANAGEMENT medicine Humans ANEMIA Omeprazole Pantoprazole Biological Specimen Banks OUTCOMES Transplantation business.industry MORTALITY OMEPRAZOLE PANTOPRAZOLE Proton Pump Inhibitors Odds ratio Iron Deficiencies Kidney Transplantation CLOPIDOGREL Pharmacodynamics Cohort proton-pump inhibitors HEART-FAILURE business medicine.drug |
| Zdroj: | Transplant International, 34(11), 2305-2316. Wiley |
| ISSN: | 1432-2277 0934-0874 |
| Popis: | Proton-pump inhibitors (PPIs) have been associated with iron deficiency (ID) in kidney transplant recipients (KTRs). Gastric acid plays a pivotal role in the intestinal absorption of non-heme iron, but the pharmacodynamics of PPIs differ in potency of acid suppression. We hypothesized that the risk of ID might be lower in KTRs using a less potent PPI. In a cohort of 724 KTRs from the TransplantLines Biobank and Cohort Study(NCT03272841), PPI use was associated with ID (odds ratio [OR] 2.02; 95% CI 1.36-2.98). Compared to no PPI use, the point estimate of the odds ratio for risk of ID for pantoprazole (OR 1.55; 95%CI 0.78-3.10) was lower than for esomeprazole and omeprazole (3.58; 95%CI 1.73-7.40 and 1.96; 95%CI 1.31-2.94, respectively). When comparing pantoprazole users with omeprazole users on an equipotent dose (≤20 omeprazole equivalents (OE)/day) omeprazole, but not pantoprazole was associated with ID, although the lack of a significant effect of pantoprazole on the risk of ID could be due to a lack of power. Furthermore, risk of ID was higher among users of a high PPI dose (≥ 20 OE/day) and OE as continuous variable was also independently associated with ID, indicating that risk of ID is higher while using a more potent PPI. Further investigation seems warranted to confirm whether pantoprazole leads to less ID in KTRs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text